LEGN (Legend Biotech) Short-Term Debt: $266 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEGN Legend Biotech Corp LEGN
74 GF Score
Price $22.70
GF Value $100.19
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Legend Biotech Short-Term Debt?

Legend Biotech LEGN -1.41% 74 Short-Term Debt is $266 Mil as of Mar. 2026. GuruFocus rates LEGN with a GF Score™ of 74/100 and a GF Value™ of $100.19 (Possible Value Trap). The stock has 3 warning signs investors should review.

Legend Biotech's Short-Term Debt for the quarter that ended in Mar. 2026 was $266 Mil.

Legend Biotech's quarterly Short-Term Debt increased from Sep. 2025 ($143 Mil) to Dec. 2025 ($319 Mil) but then declined from Dec. 2025 ($319 Mil) to Mar. 2026 ($266 Mil).

Legend Biotech's annual Short-Term Debt stayed the same from Dec. 2023 ($0 Mil) to Dec. 2024 ($0 Mil) but then increased from Dec. 2024 ($0 Mil) to Dec. 2025 ($319 Mil).

Legend Biotech Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Legend Biotech Short-Term Debt Related Terms

Legend Biotech Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Legend Biotech's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Legend Biotech Short-Term Debt Chart

Legend Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 319.10

Legend Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 142.87 319.10 266.00
LEGN
74GF Score
Legend Biotech Corp LEGN
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $266 Mil mean?
Legend Biotech (LEGN) has a Short-Term Debt of $266 Mil as of Mar. 2026.
Is Legend Biotech's Short-Term Debt too high?
Legend Biotech's current Short-Term Debt is $266 Mil. Overall, Legend Biotech has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Short-Term Debt compare to TVTX and ORKA?
Legend Biotech's Short-Term Debt of $266 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Legend Biotech's current Short-Term Debt is $266 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $100.19, compared to a current price of $22.70 — trading 77.3% below its estimated fair value. The current Short-Term Debt is $266 Mil. Legend Biotech's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Short-Term Debt is $266 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Legend Biotech (LEGN) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of $22.70 is trading 77.3% below its estimated GF Value™ of $100.19. GuruFocus considers Legend Biotech to be Possible Value Trap.

Key valuation signals for LEGN:

  • Short-Term Debt: $266 Mil
  • GF Value™: $100.19 vs. price of $22.70 (77.3% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Legend Biotech Business Description

Other Exchanges 9LB:Germany
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
74GF Score

Get the complete analysis for LEGN

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.70
Price
$100.19
GF Value